Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.PMID:38653368 | DOI:10.1016/j.ad.2024.04.017 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - April 23, 2024 Category: Dermatology Authors: R Izu-Belloso I Gainza-Apraiz P Ortiz-Romero O Servitje-Bedate R Fern ández de Misa-Cabrera Y Pe ñate-Santana B Hernandez-Machin T Estrach-Panella M Llamas-Velasco J I Yanguas-Bayona M Morillo-Andujar E Acebo-Mari ñas S Perez-Gala J C Armario-Hita P Sa Source Type: research
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
CONCLUSION: This study provides an overview of the clinical impact of CMV reactivation in patients with PCD treated with anti-CD38 mAb-containing regimens.PMID:38653670 | DOI:10.1016/j.clml.2024.03.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 23, 2024 Category: Cancer & Oncology Authors: Naohiro Matsunaga Tomotaka Suzuki Nozomi Nishitarumizu Yoko Nakanishi Aki Kondo Yukiyasu Kato Toru Ebina Yoshiaki Marumo Tomoyuki Nakamura Takahiro Nakashima Shiori Kinoshita Tomoko Narita Masaki Ri Shigeru Kusumoto Hirokazu Komatsu Shinsuke Iida Source Type: research
An analysis of the effects of chronic low dose-rate radiation exposure on cancer focusing on the differences among cancer types
CONCLUSIONS: The analysis showed that the occurrence and mean lifespan are affected in both malignant lymphomas and solid cancers. The shortening of the progression period is only seen in malignant lymphoma, no significant change was observed in solid cancers.PMID:38652836 | DOI:10.1080/09553002.2024.2338551 (Source: International Journal of Radiation Biology)
Source: International Journal of Radiation Biology - April 23, 2024 Category: Radiology Authors: Tetsuhiro Kinugawa Ignacia Braga Tanaka Satoshi Tanaka Yuichiro Manabe Fuminobu Sato Takahiro Wada Source Type: research
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects
Cell Transplant. 2024 Jan-Dec;33:9636897241247951. doi: 10.1177/09636897241247951.ABSTRACTHematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying prolonged cytopenia and the relationship between persistent cytopenia, efficacy, and AEs after anti-CD19 CAR T cell therapy are unknown. Therefore, this study explored whether persistent cytopenia after anti-CD19 CAR T cell therapy in patients with R/R DLBCL can predict therapeutic efficacy and AEs. Thi...
Source: Cell Transplantation - April 23, 2024 Category: Cytology Authors: Jingyi Li Juan Mu Jia Wang Xin Li Qing Li Yili Jiang Rui Cui Qi Deng Source Type: research
Reclaiming Self-Balancing on a Tightrope Across Time a grounded theory of transition to survivorship in older adult blood cancer survivors
CONCLUSIONS: The transition to survivorship in older adult blood cancer survivors is a complex process because of age and disease type.IMPLICATIONS: Age-related aspects of one's sense of self and its relation to health, well-being and quality of life, as older adult blood cancer survivors advance into older age need further research. Ageism and its impact on cancer survivorship care in older adults should also be explored.IMPACT: What problem did the study address?: Existing theoretical frameworks do not explain the complex process of transition to survivorship for older adult blood cancer survivors. What were the main fin...
Source: Adv Data - April 23, 2024 Category: Epidemiology Authors: Sylvia K Wood Source Type: research
Long-term remission after upfront autologous hematopoietic stem cell transplant for CD5 < sup > + < /sup > diffuse large-B cell lymphoma
J Chemother. 2024 Apr 23:1-9. doi: 10.1080/1120009X.2024.2340147. Online ahead of print.ABSTRACTCD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and ni...
Source: Journal of Chemotherapy - April 23, 2024 Category: Cancer & Oncology Authors: Yosuke Masamoto Akira Honda Aya Shinozaki-Ushiku Tetsuo Ushiku Mineo Kurokawa Source Type: research
An analysis of the effects of chronic low dose-rate radiation exposure on cancer focusing on the differences among cancer types
CONCLUSIONS: The analysis showed that the occurrence and mean lifespan are affected in both malignant lymphomas and solid cancers. The shortening of the progression period is only seen in malignant lymphoma, no significant change was observed in solid cancers.PMID:38652836 | DOI:10.1080/09553002.2024.2338551 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Kinugawa Ignacia Braga Tanaka Satoshi Tanaka Yuichiro Manabe Fuminobu Sato Takahiro Wada Source Type: research
A case of diffuse large B ‐cell lymphoma with decompensated alcohol‐related liver cirrhosis treated successfully by chemoimmunotherapy
This report describes a case of diffuse large B-cell lymphoma with MYD88 L265P and KM2DT mutation and decompensated alcohol-related liver cirrhosis. And the treatment is successful in this patient, who had multiple complications and poor prognostic factors.AbstractThis report describes a case of diffuse large B-cell lymphoma with MYD88 L265P and KM2DT mutation and decompensated alcohol-related liver cirrhosis. The lymphoma showed a complete response with no MYD88 L265P mutation after four courses of combination chemotherapy. Lymphoma is one of the most common malignant tumors, but cases of DLBCL with cirrhosis are much rar...
Source: Clinical Case Reports - April 23, 2024 Category: General Medicine Authors: Yan Li,
Ling ‐zhijie Kong Tags: CASE REPORT Source Type: research
GSE262491 XPO1 blockade with KPT-330 promotes apoptosis in Cutaneous T- cell Lymphoma by activating the p53-p21 and p27 pathways
Contributors : Nitin Chakravarti ; Amy Boles ; Rachel Burzinski ; Paola Sindaco ; Colleen Isabelle ; Kathleen McConnell ; Anjali Mishra ; Pierluigi PorcuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo assess the effects of XPO1 inhibition with small molecule inhibitor KPT-330 on Cutaneous T-cell Lymphoma after 48 hours of treatment (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 23, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
We examined rad... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - April 23, 2024 Category: Hematology Authors: Doris Leithner, Jessica R. Flynn, Sean M. Devlin, Audrey Mauguen, Teng Fei, Shang Zeng, Junting Zheng, Brandon S. Imber, Harper Hubbeling, Marius E. Mayerhoefer, Akshay Bedmutha, Efrat Luttwak, Magdalena Corona, Parastoo B. Dahi, Alejandro Luna de Abia, I Tags: Correspondence Source Type: research
Correspondence to C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients
(Source: Neurosurgical Review)
Source: Neurosurgical Review - April 23, 2024 Category: Neurosurgery Source Type: research
Shared genetic factors and causal association between chronic hepatitis C infection and diffuse large B cell lymphoma
Epidemiological research and systematic meta-analyses indicate a higher risk of B-cell lymphomas in patients with chronic hepatitis C virus (HCV) compared to non-infected individuals. However, the genetic link... (Source: Infectious Agents and Cancer)
Source: Infectious Agents and Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Leihua Fu, Jieni Yu, Zhe Chen, Feidan Gao, Zhijian Zhang, Jiaping Fu, Weiying Feng, Pan Hong and Jing Jin Tags: Research Source Type: research
Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease
Follicular lymphoma (FL) is a highly treatable, indolent non-Hodgkin lymphoma. Although FL is considered incurable, a patient without progression of disease by 24 months after treatment is predicted to have a survival consistent with persons without lymphoma. Using a sensitive assessment of minimal residual disease (MRD), we tested the hypothesis that MRD monitoring can predict long term remissions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 23, 2024 Category: Hematology Authors: Ayushi Chauhan, Lai Catherine, Frank Kuhr, Heidi Simmons, Bruce D. Cheson Source Type: research
Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors
ConclusionsAdherence to the screening guidelines in the Dutch HL survivorship care program was reasonable to good and a substantial number of actionable (risk factors for) CVD were diagnosed.Implications for Cancer Survivors.Our findings inform HL survivors at high risk of late cardiotoxicity about cardiovascular screening findings and demonstrate appropriate therapeutic actions after diagnosis of (risk factors for) CVD. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - April 23, 2024 Category: Cancer & Oncology Source Type: research
